MET and neoplasm: Relevant findings in our lab demonstrate that HGF/c-Met signaling drives brain CSC phenotype by inducing reprogramming transcription factors [37] and that inhibiting this axis in vivo depletes tumors of their tumor-initiating capacity [52].